Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0U1HX
|
|||
| Former ID |
DIB002071
|
|||
| Drug Name |
DIMS-0150
|
|||
| Synonyms |
Kappaproct; Antisense NF-kBp65 oligonucleotide (IBD), InDex Pharmaceuticals; Antisense NF-kBp65 oligonucleotide (IBD), Serono; Antisense NF-kBp65 oligonucleotide (inflammatory bowel disease), Serono
Click to Show/Hide
|
|||
| Drug Type |
Antisense drug
|
|||
| Indication | Ulcerative colitis [ICD-11: DD71; ICD-9: 556] | Phase 3 | [1] | |
| Company |
Karolinska Institute
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01493960) The Efficacy and Safety of Kappaproct in Chronic Active Treatment Refractory Ulcerative Colitis Patients. U.S. National Institutes of Health. | |||
| REF 2 | News and Analysis. Nature Reviews Drug Discovery 12, 179 (March 2013). | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.